

### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


## **Single Technology Appraisal**

# Deuruxolitinib for treating severe alopecia areata ID6597

### **Provisional Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
Company	<u>General</u>
Sun Pharma (deuruxolitinib)	<ul> <li>All Wales Therapeutics and Toxicology Centre</li> </ul>
Patient/carer groups	Allied Health Professionals Federation
Alopecia UK	Board of Community Health Councils in
Changing Faces	Wales
Gene People	<ul> <li>British National Formulary</li> </ul>
Genetic Alliance UK	Care Quality Commission
South Asian Health Foundation	<ul> <li>Department of Health - Northern Ireland</li> </ul>
Specialised Healthcare Alliance	<ul> <li>Healthcare Improvement Scotland</li> </ul>
	<ul> <li>Medicines and Healthcare products</li> </ul>
Healthcare professional groups	Regulatory Agency
Association of Genetic Nurses &	National Association of Primary Care
Counsellors	National Pharmacy Association
British Association of Dermatologists	NHS Confederation
British Dermatological Nursing Group	NHS Wales Joint Commissioning
British Geriatrics Society	Committee
British Hair and Nail Society  British Olive Formulation	Scottish Medicines Consortium
British Skin Foundation  British Consists for Output Alleger	Welsh Government
British Society for Cutaneous Allergy      Dritish Society for Countie Madicine	Possible comparator companies
British Society for Genetic Medicine      Drive and Core Portracted and Consister	<ul><li>Possible comparator companies</li><li>Pfizer (ritlecitinib)</li></ul>
Primary Care Dermatology Society     Payal Callage of Capacal Practitionary	• Flizer (Illiecitifilib)
Royal College of General Practitioners     Royal College of Nursing	Relevant research groups
<ul><li>Royal College of Nursing</li><li>Royal College of Pathologists</li></ul>	British Society of Immunology
<ul><li>Royal College of Pathologists</li><li>Royal College of Physicians</li></ul>	Cochrane Skin Group
Royal College of Fifysicians     Royal Pharmaceutical Society	Cochrane Cystic Fibrosis & Genetic
Royal Society of Medicine	Disorders Group
St John's Institute of Dermatology	Genomics England
UK Clinical Pharmacy Association	MRC Clinical Trials Unit
2. Commod Filannady / 10000iation	National Institute for Health Research
Others	
Department of Health and Social Care	Associated Public Health groups
NHS England	Public Health Wales
	UK Health Security Agency

Provisional stakeholder list for the evaluation of deuruxolitinib for treating severe alopecia areata ID6597



NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

## Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.